![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
MB McClurkan, JL Valentine, L Arnold and SM Owens
Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock.
Treatment of drug toxicity is problematic for compounds like phencyclidine (PCP) which have no known antagonists. With the advent of technology for production of large amounts of monoclonal antibody, it is now possible to explore the use of these antibodies as high affinity in vivo antagonists for treatment of PCP overdose. In the current study, the pharmacokinetics of an anti-PCP monoclonal antibody Fab (antigen binding fragment of immunoglobulin G) were determined in adult male Sprague-Dawley rats (n = 5). Each animal was cannulated and dosed with approximately 0.12 g/kg of unlabeled anti-PCP Fab fragments (Kd for PCP = 1.8 +/- 0.27 nM) along with a tracer dose of anti-PCP [3H]Fab. Blood was drawn at predetermined intervals and serum was analyzed for total radioactivity by liquid scintillation spectrometry. Serum and urine were analyzed for intact anti-PCP [3H]Fab after fractionation on a high-performance liquid chromatography molecular weight sizing column followed by quantitation by liquid scintillation spectrometry. The pharmacokinetic parameters for the [3H]Fab in rat serum were a terminal elimination T1/2 of 7.5 hr (harmonic mean), a volume of the central compartment of 0.17 +/- 0.026 liters/kg and a steady-state volume of distribution of 0.55 +/- 0.15 liters/kg (mean +/- S.D.). Systemic and renal clearances were 2.7 +/- 0.9 and 0.47 +/- 0.24 ml/min/kg, respectively. The total amount of the radioactive dose ([3H] Fab plus radioactive catabolic products) appearing in the urine was 51 +/- 11%, whereas urinary excretion of intact [3H]Fab accounted for 21 +/- 15% of the total dose. All animals tolerated the Fab infusion without adverse effect.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  E. C. Peterson, E. M. Laurenzana, W. T. Atchley, H. P. Hendrickson, and S. M. Owens Development and Preclinical Testing of a High-Affinity Single-Chain Antibody against (+)-Methamphetamine J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 124 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Keyler, S. A. Roiko, E. Benlhabib, M. G. LeSage, J. V. St. Peter, S. Stewart, S. Fuller, C. T. Le, and P. R. Pentel MONOCLONAL NICOTINE-SPECIFIC ANTIBODIES REDUCE NICOTINE DISTRIBUTION TO BRAIN IN RATS: DOSE- AND AFFINITY-RESPONSE RELATIONSHIPS Drug Metab. Dispos., July 1, 2005; 33(7): 1056 - 1061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Proksch, W. B. Gentry, and S. M. Owens Anti-Phencyclidine Monoclonal Antibodies Provide Long-Term Reductions in Brain Phencyclidine Concentrations during Chronic Phencyclidine Administration in Rats J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 831 - 837. [Abstract] [Full Text]
|
|
|
|
|
|
J. W. Proksch, W. B. Gentry, and S. M. Owens Pharmacokinetic Mechanisms for Obtaining High Renal Coelimination of Phencyclidine and a Monoclonal Antiphencyclidine Antigen-Binding Fragment of Immunoglobulin G in the Rat J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 616 - 624. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Lim, S. M. Owens, L. Arnold, J. C. Sacchettini, and D. S. Linthicum Crystal Structure of Monoclonal 6B5 Fab Complexed with Phencyclidine J. Biol. Chem., October 30, 1998; 273(44): 28576 - 28582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Hardin, W. D. Wessinger, J. W. Proksch, and S. M. Owens Pharmacodynamics of a Monoclonal Antiphencyclidine Fab with Broad Selectivity for Phencyclidine-Like Drugs1 J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1113 - 1122. [Abstract] [Full Text]
|
|
|
|
|
|
G. Rivière, V. Choumet, B. Saliou, M. Debray, and C. Bon Absorption and Elimination of Viper Venom after Antivenom Administration J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 490 - 495. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
